



**CALMUN'25
ORGANIZATION OF
AMERICAN STATES
STUDY GUIDE**



Agenda Item: Combating the Opioid Epidemic and Drug Abuse

Academic Assistant: Azra Kayar

Table of Contents:

1. Letter from the Secretary-General
2. Glossary
3. Introduction
4. History
5. Pharmaceutical Companies' and Cartels' Impact on Opioid Addiction
6. Rehabilitation Centers
7. Societal Challenges Arising from the Opioid Crisis
8. Major Parties and Stakeholders Involved
9. Possible Solutions
10. Points to Cover
11. Resources and Links for Further Research

1. Letter from the Secretary-General

Esteemed Participants,

As the Secretary-General of Cağaloğlu Model United Nations, it is my distinct honor to welcome you all to the 7th edition of CALMUN, which will take place on May 16th, 17th, and 18th, 2025. It is with great pleasure that we present the study guide for OAS, which aims to equip you with the essential knowledge and context for the upcoming three days.

After months of preparation and dedicated effort, I am proud to say that we are now just one step away from CALMUN 2025. We hope that, by reading this guide, you will feel as ready and enthusiastic as we are.

Without a doubt, this conference would not be possible without the contributions of our remarkable academic team. I extend my gratitude to our Head of Academy, Özge Öztürk; our Co-Heads of Crisis, Meryem Sultan Çok and Akay Engin; our devoted and hardworking team members; and our motivated trainees. Their commitment and passion have brought this vision to life and elevated CALMUN's academic quality to its peak.

Furthermore, I would also like to extend my best wishes to all delegates participating in CALMUN 2025. Whether this is your first conference or you are a seasoned MUNer, I thank each of you for taking a step forward and joining us. We truly hope that CALMUN will be a special experience that you will remember warmly in the future. From my perspective, MUN is about motivation, enjoyment, meaningful discussion, and connection. I wish each delegate an inspiring, engaging, and memorable experience.

Warm regards,

Ceylin Gürsoy

Secretary-General

2. Glossary

Opioid: Chemical substances used as painkillers with addictive properties. Drugs such as morphine, oxycodone, and fentanyl are among opioids.

Prescription Drug: Medicines given under the supervision of a doctor and used for medical purposes. Some prescription drugs, such as opioids, can lead to addiction.

Drug Cartels: Organized criminal groups that manage the production, trafficking, and distribution of drugs. Especially in Latin America, cartels cause major security problems.

Harm Reduction: Strategies against drug addiction that aim to reduce the harms of addiction rather than ending it completely.

Overdose: Poisoning that occurs as a result of taking more substances than the body can handle.

Rehabilitation Centers: Centers where individuals struggling with addiction receive treatment and support to overcome drug dependency. Their goal is to help individuals recover and successfully reintegrate into society.

Medical Use of Drugs: Use of drugs for medical and scientific purposes only. Today, the raw materials of medical drugs are the most effective method for treating most psychological diseases.

Fentanyl: A synthetic opioid with a strong pain-relieving effect, but can be fatal even at very low doses. Fentanyl overdoses kill thousands of people every year.

International Narcotics Control Board (INCB): United Nations body that monitors drug production and marketing.

Marijuana: An herbal drug usually used for recreational or medicinal purposes.

Prescription Monitoring: A system that monitors drug distribution between doctors and pharmacies to prevent misuse of prescription drugs.


3. Introduction

The use of drugs, both natural and synthetic, has a long history in human societies, originally for medical treatment and, in some cases, recreational or ceremonial purposes. With the advancement of science and technology, naturally derived substances were transformed into more potent chemical compounds and began to be produced in various forms such as pills, injections, and capsules. While these developments have led to major improvements in pain management and medical care, they have also increased the risk of dependency, misuse, and addiction.


In recent decades, the misuse of opioids, a class of drugs primarily used for pain relief, has become a major public health concern, particularly in countries across the American continent. Opioids such as morphine, oxycodone, hydrocodone, and fentanyl are commonly prescribed to manage moderate to severe pain. However, their high potential for addiction has contributed to a significant rise in substance use disorders and overdose-related deaths.

Within the region covered by the Organization of American States (OAS), the opioid crisis has had a profound impact on public health, security, and social stability. The increased availability of both prescription opioids and illegally trafficked substances has led to rising addiction rates in many member states. In addition to health-related consequences, drug misuse contributes to economic challenges, family breakdown, and criminal activity. The role of drug trafficking organizations, particularly in Central and South America, has further complicated the situation by fueling violence and weakening institutions.

Although opioids are legally distributed under medical supervision, there have been numerous cases where prescriptions have been misused, diverted, or sold illegally. In some instances, individuals have obtained opioids through fraudulent means or resorted to more dangerous alternatives, such as heroin or synthetic fentanyl, when prescriptions became unavailable. These patterns have contributed to a significant increase in opioid-related deaths, especially in the United States and Canada.



Furthermore, data on medical opioid use also highlights regional disparities. The graph below demonstrates that per capita morphine consumption in the Americas, particularly in countries such as Argentina and the United States, is significantly higher than the global average. These figures provide a quantitative foundation for understanding both the medical and non-medical dimensions of opioid use across OAS member states.



In response to these challenges, some OAS member states have implemented national strategies focused on limiting opioid prescriptions, expanding access to treatment, and improving public awareness. Others have debated alternative approaches such as the decriminalization or regulation of certain substances, with the aim of reducing the power of illegal drug markets and prioritizing public health interventions. However, the diversity of national policies and levels of institutional capacity has made regional coordination difficult.

4. History

a. Early Era of International Drug Control

Efforts to regulate the use and distribution of narcotic substances across the American continent—and globally—began in the early 20th century. During this period, the absence of consistent legal frameworks and enforcement mechanisms allowed for the widespread circulation, misuse, and illicit trade of drugs such as opium, morphine, and cocaine. These conditions contributed to rising levels of drug dependence and overdose, prompting the international community to pursue multilateral regulation.

In response, the [International Opium Convention \(1912\)](#) was adopted at The Hague, representing the first global agreement aimed at limiting the non-medical use of narcotic substances. The convention introduced a series of obligations for signatory states, including:

- Restricting the use of drugs such as opium, morphine, and cocaine exclusively to medical and scientific purposes.
- Placing the production, distribution, and sale of these substances under government control, while allowing licensed private entities to operate under state authorization.
- Requiring states to maintain official records of drug production, import, and export, and to share such records internationally when necessary.
- Promoting cross-border cooperation in cases involving illicit trafficking and organized drug smuggling.
- Limiting opium production solely to medical purposes, with sanctions applicable to states that failed to comply.

While the 1912 Convention was an important initial step, it was eventually deemed insufficient to address the growing complexities of the international drug trade. This led to the adoption of the [International Opium Convention of 1925](#), which expanded the scope of international control.

This second agreement introduced more rigorous provisions, including:

- Stricter control over the production, sale, and use of opium, morphine, and cocaine.
- The establishment of maximum production limits for narcotic substances within each country.
- Mandatory licensing systems for the import and export of controlled drugs.
- Requirements for detailed recordkeeping and public reporting of national drug statistics.
- Penal sanctions, including imprisonment, for those engaged in drug smuggling.
- The inclusion of certain synthetic substances within the scope of control.
- The establishment of an international supervisory body empowered to oversee national compliance and intervene when necessary.

As drug-related challenges continued to evolve, the need for a more unified and comprehensive approach became apparent. This led to the adoption of the [Single Convention on Narcotic Drugs \(1961\)](#), which secured previous treaties and created a global framework for drug control that remains in force today.

Key provisions of the 1961 Convention include:

- Allowing the use of controlled substances, such as opium, marijuana, morphine, heroin, and cocaine, only for medical and scientific purposes.
- Requiring all parties to establish a national drug control system to monitor and regulate drug activities.
- Obligating states to report production estimates to the United Nations to ensure alignment with legitimate medical needs.
- Mandating the licensing of producers and distributors, and promoting efforts to combat trafficking.
- Categorizing drugs into four schedules, with Schedule I substances considered the most harmful and subject to the highest level of control.

- Establishing the International Narcotics Control Board (INCB) to monitor state compliance with the convention.
- Placing raw materials used in drug production under strict governmental oversight.
- Recognizing drug addiction as a social and public health issue, and encouraging the development of rehabilitation centers and support services.
- Explicitly rejecting the legalization of drugs for recreational use, reinforcing the health- and security-focused nature of the treaty.

Although the 1961 Convention represented the most comprehensive legal framework of its time, it has also generated ongoing policy debate. In recent years, the final article has become a subject of discussion within several OAS member states, some of which are considering alternative approaches to reduce the harm associated with drug use and trafficking. These evolving national policies highlight the broader tension between international commitments and domestic policy experimentation.

b. The Drug Market in South and Latin America

Beginning in the mid-20th century, the proliferation of organized drug trafficking networks significantly transformed the political and economic landscape of several South and Latin American countries. In particular, nations such as Colombia, Peru, and Bolivia became major centers for the cultivation, production, and distribution of illicit narcotics, including cocaine and, more recently, synthetic opioids. The growing influence of drug cartels in these regions contributed to the emergence of a large, transnational drug market that remains active to this day.

While drug production has generated considerable profit for trafficking organizations, it has also fostered systemic corruption, fueled organized crime, and undermined state institutions. In many cases, communities affected by the drug trade have experienced increased violence, extortion, and political instability. Armed groups and criminal networks have frequently used violent tactics to expand territorial control, challenge government authority, and eliminate rival factions. These dynamics have placed considerable strain on governance structures and, in some cases, contributed to the weakening or erosion of state legitimacy.


Public health and safety have also been affected. Although not all drug use leads to violence, certain substances, particularly when unregulated or consumed in unsafe environments, can impair judgment and increase the risk of harm to both the user and others. In areas with limited access to treatment and prevention services, the social consequences of addiction can be particularly severe.

In response to the growing power of drug trafficking organizations, the United States launched the "War on Drugs" in the 1970s, a campaign that aimed to reduce both domestic drug use and the international drug supply. This strategy included military-style operations, law enforcement cooperation, and financial support for anti-drug initiatives in partner countries across Latin America. While these efforts led to a number of arrests and seizures, they often failed to address the structural causes of the drug trade, such as poverty, lack of economic alternatives, and weak institutional frameworks.

Despite decades of intervention, drug cartels have remained resilient, often adapting their strategies through corruption, innovation in trafficking methods, and the expansion into new markets. The persistence of these networks has raised important questions about the long-term effectiveness of enforcement-based approaches and has prompted calls for more comprehensive strategies that also incorporate public health, development, and human rights perspectives.

c. The Increase of Opioid Addiction Throughout the Continent

In the early 21st century, both the United States and Canada experienced a sharp and sustained increase in opioid use and dependency, a development that has come to be widely recognized as the "Opioid Crisis" in the Americas. This period has been characterized by a significant rise in addiction rates, hospitalizations, and fatalities linked to both prescription and illicit opioids. One of the primary contributing factors to this crisis has been the conduct of several major pharmaceutical companies, which promoted opioid medications as safe and non-addictive for long-term pain management. These marketing strategies, influenced prescribing practices across the healthcare sector and led to a rise in the availability of opioids. Over time, this widespread access facilitated misuse, dependency, and, in many cases, a transition to more powerful and unregulated substances such as heroin and synthetic fentanyl. Consequently, opioid-related deaths in North America have reached record levels.



The chart above shows the number of deaths per 100,000 people in the United States due to opioids and heroin, which were produced by morphine from 1999 to 2020.

d. Legalization of Drugs in OAS Governments

While many OAS member states continue to uphold prohibition-based drug policies, others have explored or implemented varying degrees of decriminalization and legalization, particularly in relation to cannabis. These policy shifts are often part of broader national debates on public health, criminal justice reform, and state control of previously illicit markets.

Uruguay is widely recognized as the first country in the world to fully legalize the production, sale, and recreational use of marijuana. This landmark reform, passed in 2013, placed the government in charge of regulating the cannabis market through state-controlled production and licensing systems. Under this framework, adult citizens are allowed to purchase limited quantities of marijuana from registered pharmacies, grow it privately, or join licensed cannabis clubs. The primary objectives of this policy were to reduce the influence of the illicit drug market, lower drug-related crime, and improve public health oversight. While some studies have reported an increase in cannabis usage following legalization, particularly among young adults, the incidence of marijuana-related criminal offenses has decreased.

Additionally, the state has generated new tax revenues and improved regulatory control over the quality and safety of cannabis products.

Following Uruguay's example, several other countries in the region have initiated discussions or legal reforms related to drug decriminalization or medical legalization. Mexico, for instance, legalized the medicinal use of marijuana in 2017 and, after years of legislative debate and court rulings, approved a bill in 2021 aimed at legalizing recreational use, although its implementation remains delayed. Advocates in Mexico argue that such reforms could help reduce the power of drug cartels and ease the pressure on the criminal justice system, but concerns remain regarding regulatory capacity and the potential for unintended consequences.

Colombia, historically associated with illicit drug production, has also taken steps toward reform. The country legalized the use of medical cannabis in 2016 and has since developed a growing legal industry for cultivation and export. Recreational use remains illegal, but the possession of small amounts for personal consumption has been decriminalized. These measures reflect an evolving approach that seeks to balance public health considerations with efforts to reduce criminal penalties for non-violent drug-related offenses.

Peru and Bolivia have engaged in similar policy discussions. Peru legalized medical marijuana in 2017 and established a regulatory framework for its production and sale. Bolivia, meanwhile, has maintained strong cultural protections for the coca leaf, which is traditionally used for medicinal and social purposes among indigenous communities. While coca cultivation remains legal in specified regions for traditional use, the Bolivian government has expressed opposition to full drug legalization, viewing it as inconsistent with the country's cultural values and international obligations.

Despite these national reforms, the topic of drug legalization remains controversial across the region. Many OAS member states continue to express skepticism about the long-term social, economic, and health impacts of legalization. Concerns include the potential for increased drug consumption, especially among youth, the challenge of regulating new markets effectively, and the risk of sending mixed messages about drug safety. In addition, international conventions, such as the 1961 Single Convention on Narcotic Drugs, place constraints on how far states can go in legalizing certain substances, requiring careful navigation of legal commitments.

As a result, while a growing number of states have experimented with various forms of legalization or decriminalization, others remain cautious or firmly opposed. This divergence reflects broader debates over the role of the state in drug policy, the effectiveness of prohibition as a deterrent, and the need to balance public health, social equity, and security concerns. These differences continue to shape the legal landscape of the Americas and present a key point of discussion for future regional cooperation and policymaking.

5. Pharmaceutical Companies' and Cartels' Impact on Opioid Addiction

The rise of the opioid crisis in the Americas is closely tied to two major players: pharmaceutical companies and drug cartels. While one operates legally and the other illegally, both have significantly contributed to the spread of opioid addiction in OAS member states.

a. The Role of Pharmaceutical Companies

In the 1990s, large pharmaceutical companies, most notably Purdue Pharma, began marketing prescription opioids as safe and effective treatments for chronic pain. One of their flagship drugs, OxyContin, was advertised as having a low risk of addiction, even though it contained oxycodone, a highly addictive opioid. Doctors, relying on these claims, began prescribing opioids at much higher rates. As a result, millions of patients were exposed to addictive substances. In 2019 alone, over 10 million Americans misused prescription opioids. That same year, nearly 50,000 deaths were recorded in the U.S. due to opioid overdoses.

Even more concerning is the rise of synthetic opioids like fentanyl, which is up to 50 times stronger than heroin. Just a small amount can be fatal. In Canada, fentanyl was responsible for 5,368 overdose deaths in 2020 alone.


In recent years, pharmaceutical companies have faced widespread criticism and lawsuits for their role in fueling the crisis. Purdue Pharma filed for bankruptcy in 2019, and the Sackler family (its owners) agreed to pay billions of dollars in settlement. These events highlighted how corporate greed, misleading marketing, and lack of regulatory oversight contributed to a public health disaster.

b. The Role of Drug Cartels

As governments began to restrict access to prescription opioids, many addicted individuals turned to illegal sources, and drug cartels filled that demand. Powerful cartels, particularly in Mexico, began trafficking illicit fentanyl and heroin, often mixing them with other drugs to increase effectiveness and profits.

Unlike regulated pharmaceutical drugs, street opioids are unpredictable in strength and often contaminated. This has caused a surge in accidental overdoses, especially in the United States. Mexican cartels, including the Sinaloa and Jalisco New Generation Cartel (CJNG), have become key suppliers of synthetic opioids to North America.

South American countries like Colombia, Peru, and Bolivia, traditionally known for cocaine production, have also become entangled in the opioid trade. Although they are not the main producers of opioids, the lack of strong law enforcement, poverty, and weakened institutions make them vulnerable to cartel influence and smuggling operations.



The chart illustrates the number of homicides committed by drug cartels per 100,000 people in South American countries, demonstrating the direct connection between organized crime and regional instability.

c. The Combined Impact

While the actions of pharmaceutical companies and drug cartels are often considered separately, the cumulative effect of both legal and illegal opioid supply chains has intensified the scale and complexity of the crisis. This challenge affects not only individual health outcomes but also public trust, institutional capacity, and regional security.

i. Transition from Prescription Use to Illicit Consumption

One of the most significant aspects of the opioid crisis is the progression from the legal use of prescription opioids to the consumption of illicit substances. Many individuals begin using opioids under medical supervision, often following surgery, injury, or chronic illness. However, in certain cases, prolonged exposure to these substances can lead to dependency. When access to prescriptions is restricted -whether due to medical guidelines, regulation, or affordability- some individuals may seek alternatives through illegal markets. Drugs such as heroin or illicitly manufactured fentanyl often serve as substitutes. These substances, while accessible, are typically unregulated and may vary in terms of effectiveness, increasing the likelihood of accidental overdose and other health complications.

ii. Pressure on Healthcare Systems

The widespread misuse of opioids has placed significant strain on healthcare systems across OAS member states. Countries with well-resourced medical infrastructures are faced with increasing demands for emergency care, addiction treatment, and long-term rehabilitation services. In states with limited healthcare access, particularly in rural or underserved areas, the challenges are more pronounced. These regions may lack both the physical infrastructure and trained personnel necessary to provide effective treatment and recovery support. As addiction and overdose cases rise, so does the demand for coordinated public health responses, which may be difficult to implement consistently across diverse national contexts.

iii. Decline in Institutional Trust

The crisis has also contributed to a broader erosion of trust in public and private institutions. In some communities, skepticism has grown toward pharmaceutical companies due to perceptions of irresponsible marketing practices and undercommunication of the risks associated with opioids. In parallel, government agencies have faced criticism for perceived regulatory gaps or insufficient oversight of prescription practices. This decline in institutional trust may result in reduced public engagement with both medical providers and policy initiatives, creating additional barriers to effective intervention. Restoring credibility and promoting transparency are, therefore, important considerations in shaping future responses.

iv. Strengthening of Illicit Drug Networks and Security Risks

As demand for opioids increased, so did the opportunities for transnational criminal organizations. Drug cartels, particularly in countries such as Mexico, have expanded their operations to include the production and distribution of synthetic opioids. These activities have generated considerable profits, which in turn have supported the growth of these groups and their influence in certain regions. In some areas, drug trafficking is accompanied by violence, corruption, and a weakening of the rule of law. These developments not only pose a challenge to public safety but can also undermine governmental authority and international stability, especially in states already confronting socio-economic hardship.

v. Challenges of Regional Coordination

Within the Organization of American States (OAS), member states have adopted a range of policy responses to address the opioid crisis. These responses reflect the diversity of political systems, legal frameworks, public health infrastructure, and socio-cultural perspectives found across the region. Although all member states share a commitment to reducing the harms associated with opioid misuse, their approaches differ considerably, which can complicate regional coordination efforts.

Several countries have taken steps to incorporate harm reduction strategies into their national drug policies. For example, Canada has implemented supervised consumption sites, expanded access to opioid substitution therapies, and developed comprehensive public education campaigns aimed at reducing stigma. Similarly, Uruguay, which became the first country to fully legalize the recreational use of marijuana, continues to explore regulatory approaches to reduce the risks associated with illicit drug markets. These countries tend to frame drug dependency as a public health issue, investing in prevention, rehabilitation, and social reintegration rather than focusing solely on punitive measures.

In contrast, other member states have maintained more prohibition-focused approaches. For instance, Mexico continues to experience significant challenges related to organized crime and drug trafficking, prompting authorities to prioritize enforcement-based responses and military interventions. Honduras and Guatemala, where cartels assert considerable influence over certain regions, have also adopted stricter legal frameworks and show caution toward harm reduction or decriminalization models.

Between these two broad policy orientations, some countries adopt hybrid approaches that combine enforcement with emerging public health measures. For example, Colombia has

taken steps to legalize medical marijuana and invest in addiction treatment programs while continuing strong enforcement actions against illicit trafficking. Argentina and Chile have legalized medical cannabis and have debated the potential benefits of decriminalization, yet they continue to enforce penalties against unauthorized drug distribution. These countries often balance reform initiatives with concerns about international obligations, domestic political climate, and resource availability.


Such divergence in national strategies presents challenges to developing a unified regional framework. Issues such as cross-border trafficking, health data sharing, pharmaceutical regulation, and extradition procedures require cooperation across jurisdictions that may have differing legal definitions and enforcement priorities. For example, a country with decriminalized possession laws may encounter coordination difficulties with neighboring states that apply mandatory sentencing for similar offenses.

6. Rehabilitation Centers

Rehabilitation centers serve a central role in addressing the opioid epidemic by supporting individuals in overcoming addiction, restoring their physical and mental health, and reintegrating them into society. Their purpose extends beyond detoxification; they offer a structured environment where patients receive medical treatment, psychological counseling, and social support. However, while their importance is widely acknowledged, a range of practical and systemic barriers often limits the effectiveness and accessibility of these services across the Organization of American States (OAS).

a. Access and Availability


A major obstacle to effective rehabilitation lies in the unequal availability of treatment centers. In many OAS countries, the distribution of services is highly centralized, with most facilities concentrated in urban areas. Rural communities, where healthcare infrastructure is often limited, face significant access gaps. Individuals living in remote regions may be required to travel long distances to reach the nearest center, which can be particularly burdensome for those with limited transportation options or financial means. These geographic differences create an environment where treatment is not equally accessible to all, potentially leaving some populations without realistic avenues for recovery. Additionally, the number of available beds or program slots is often insufficient to meet growing demand, leading to long waiting times that can discourage individuals from seeking help at a critical moment in their addiction.



Number of addiction treatment centers in the United States between 2003-2020

b. Financial Barriers

The financial cost of rehabilitation poses another considerable challenge. In countries where public healthcare systems do not fully cover addiction treatment, patients may be required to pay for services out of pocket. These costs can be substantial, particularly for long-term residential programs, specialized therapies, or private clinics. As a result, individuals from low-income backgrounds may find it difficult or impossible to access care. Even in countries with partial public funding, additional expenses, such as transportation, childcare, or lost income during treatment, may create further obstacles. In contrast, wealthier individuals often have more options and can access higher-quality or more comprehensive services. This disparity contributes to unequal outcomes and may perpetuate cycles of addiction in disadvantaged communities.



c. Staffing and Quality of Care

The quality and effectiveness of rehabilitation centers are closely linked to the qualifications and availability of healthcare professionals. A well-functioning center typically requires a multidisciplinary team, including physicians, psychiatrists, addiction counselors, social workers, and vocational support staff. However, many facilities, particularly those operating in under-resourced settings, suffer from chronic shortages of trained personnel. This can lead to inconsistent care, inadequate monitoring, and reliance on outdated or generalized treatment methods that do not fully address the complex nature of opioid addiction. Furthermore, without regular training and supervision, existing staff may lack up-to-date knowledge of evidence-based practices or emerging therapies. These limitations not only reduce the effectiveness of treatment but may also impact patient safety and long-term outcomes.

d. Social Stigma and Public Perception

Social attitudes toward addiction represent another significant barrier to rehabilitation. In many societies, individuals who misuse drugs are often viewed through a moral or criminal lens, rather than as individuals facing a medical condition that requires treatment. This stigma can discourage people from seeking help due to fear of judgment, discrimination, or social exclusion. Even after completing treatment, individuals in recovery may face ongoing prejudice that affects their ability to find employment, housing, or support networks. Public misperceptions may also influence policy decisions, leading to an overemphasis on disciplinary measures rather than health-based responses. Addressing this issue requires long-term public education efforts to shift perceptions and promote understanding of substance use disorders as complex, multifactorial health conditions.

e. Rehabilitation vs. Incarceration

Comparative research has shown that rehabilitation tends to produce more favorable long-term outcomes than incarceration in cases of substance use disorders. Treatment-focused approaches address the root causes of addiction and equip individuals with coping mechanisms, skills, and support systems needed for recovery. In contrast, imprisonment often fails to provide adequate healthcare or psychological support and may expose individuals to additional trauma or unsafe conditions. Furthermore, incarceration can disrupt family relationships, employment, and education, all of which are important factors in sustained recovery. A number of studies indicate that individuals who receive structured treatment have lower rates of relapse and reoffending compared to those who serve prison sentences without access to addiction services.

f. Reintegration and Long-Term Support

Successful rehabilitation requires more than clinical treatment alone. Long-term recovery is heavily influenced by the support available after an individual leaves a rehabilitation center. Reintegration into society involves finding stable housing, securing employment, rebuilding family and social relationships, and continuing mental health care. Without these forms of support, individuals may return to environments that contributed to their initial substance use or face new challenges that trigger relapse. Unfortunately, post-treatment services are often underdeveloped or underfunded, particularly in lower-income regions. The absence of coordinated reintegration programs limits the effectiveness of rehabilitation and may result in repeated cycles of treatment and relapse. Expanding access to aftercare services and community-based support systems is, therefore, critical to reducing recidivism and promoting lasting recovery.

7. Societal Challenges Arising from the Opioid Crisis

The opioid epidemic presents not only a public health emergency but also a broader societal crisis with far-reaching consequences for human rights, national economies, and social structures. These interconnected challenges create substantial policy dilemmas that require attention from both national governments and regional organizations such as the Organization of American States (OAS). Understanding the depth and scope of these issues is essential for delegates aiming to develop meaningful, realistic, and sustainable responses.

a. Human Rights and Ethical Dilemmas

One of the most pressing concerns raised by the opioid crisis is its intersection with fundamental human rights. The right to health, as articulated in international legal instruments such as the Universal Declaration of Human Rights and the International Covenant on Economic, Social, and Cultural Rights, implies that all individuals should have equal access to healthcare services, including addiction treatment. In practice, however, access is often uneven, with marginalized communities -including low-income groups, rural populations, and indigenous communities- facing significant barriers to treatment and rehabilitation services.

A further ethical debate centers on the criminalization of individuals with substance use disorders. In many jurisdictions, people struggling with opioid dependence are processed through the criminal justice system rather than being offered medical or psychological care. This approach has raised questions about whether it aligns with human rights principles and public health best practices. The existence of safe injection sites and needle exchange programs in some countries has sparked additional ethical discussions. While such harm reduction strategies aim to minimize health risks and mortality, they remain controversial in parts of the Americas due to legal, cultural, and moral concerns.

Individuals in recovery also face persistent social stigma and discrimination, which may limit their access to housing, employment, and education. This societal marginalization can contribute to relapse and make reintegration into the community more difficult, raising further questions about the inclusivity and fairness of existing drug policy frameworks.

b. Economic Strain on Public and Private Systems

The opioid epidemic imposes a significant economic burden on OAS member states. These costs manifest across multiple sectors, including healthcare, law enforcement, social services, and the labor market. Governments are often required to allocate substantial resources toward emergency medical care, addiction treatment, and public safety operations, placing strain on already limited public budgets, particularly in lower-income countries.

Indirect economic consequences are also substantial. The loss of productivity due to illness, disability, or death reduces overall workforce participation and can hinder national development efforts. Employers may face challenges related to absenteeism, decreased performance, or occupational accidents linked to substance misuse. In regions where drug trafficking is prevalent, the influence of organized crime networks can distort local economies, reduce investor confidence, and weaken the rule of law.

The economic debate surrounding incarceration versus rehabilitation is particularly relevant. Incarceration typically involves high costs without addressing the root causes of addiction, while treatment-based models, although initially expensive, have been shown in some cases to be more cost-effective in the long term. However, the up-front investment required for establishing comprehensive rehabilitation systems can be a barrier for states with limited tax capacity, presenting a significant policy challenge.


c. Gaps in Prevention, Awareness, and Early Intervention

Although much attention has been paid to treatment and enforcement, prevention remains a frequently underdeveloped aspect of national drug strategies. Many countries lack consistent, evidence-based education programs that address substance use from an early age. School curricula may fail to incorporate health education related to drug risks, and in some cases, prevention efforts are either outdated or overly disciplinary, potentially reducing their effectiveness.

Public awareness campaigns also vary widely in scope, quality, and cultural relevance. In the absence of reliable information, myths and misinformation about opioids continue to circulate, contributing to unsafe practices and the stigmatization of addiction. Media portrayals of drug use may sensationalize or oversimplify the issue, leading to further confusion among the general public.

Family and community structures also play an important role in prevention, yet support systems for parents, teachers, and local organizations are often lacking. Youth in vulnerable environments - such as those experiencing poverty, violence, or family instability - may be at greater risk of substance misuse due to a lack of protective factors. Reaching these individuals before addiction begins is critical, but many states do not have the necessary outreach infrastructure or targeted programming in place.

8. Major Parties And Stakeholders Involved



United States of America: The United States continues to experience one of the most severe opioid epidemics globally, with high rates of prescription drug misuse, heroin use, and fentanyl-related overdose deaths. Federal and state authorities have adopted a multifaceted

response that includes stricter prescribing regulations, expanded use of prescription drug monitoring programs (PDMPs), and increased funding for prevention, treatment, and recovery services. Medication-assisted treatment (MAT) and behavioral health programs are promoted across public healthcare systems, while public education campaigns seek to raise awareness and reduce stigma.

In parallel, the legal status of marijuana varies across the country. While cannabis remains illegal under federal law, a growing number of states have legalized its use for medical or recreational purposes. This complex policy environment has led to continued debate regarding the relationship between cannabis legalization and opioid use trends.



Canada: Canada has faced a substantial increase in opioid-related deaths, particularly due to the proliferation of synthetic opioids such as fentanyl and its analogues. The government has declared the crisis a public health emergency in several provinces and has implemented harm reduction strategies

such as supervised consumption sites, needle exchange programs, and naloxone distribution. These efforts are supported by the Canadian healthcare system, which provides universal access to addiction treatment and mental health services.

Marijuana was fully legalized at the federal level in 2018, making Canada one of the first countries to regulate recreational cannabis nationwide. The Canadian government continues to monitor the effects of this policy while maintaining a strong focus on opioid misuse prevention and treatment.



Mexico: Mexico plays a dual role in the regional drug landscape: while it faces challenges related to domestic drug use, it is also a major transit and production zone for narcotics, including fentanyl and other synthetic opioids destined primarily for the United States. Drug trafficking organizations, particularly powerful cartels, have a significant impact on national security and law enforcement efforts.

Although marijuana has been decriminalized for medical use and the Supreme Court has ruled in favor of recreational use on several occasions, comprehensive legislation on legalization remains under debate. The Mexican government continues to combat trafficking and violence while cautiously engaging in policy discussions on regulated drug markets and harm reduction.



Colombia: Colombia has traditionally been associated with the production of coca, the raw material for cocaine, but it is increasingly involved in broader drug policy reforms. The government legalized medical marijuana in 2016 and has developed a regulated cannabis industry for export. However, recreational cannabis remains prohibited, and opioid addiction is not as prevalent as it is in other parts of the Americas.

Colombia maintains strong cooperation with the United States on anti-drug operations and continues to combat organized crime and illegal drug trafficking. While harm reduction is gaining attention in public discourse, enforcement and security priorities remain central to national drug policy.



Peru: Peru is one of the world's top producers of coca leaf, with a significant portion of illicit production destined for cocaine manufacturing. Opioid addiction rates remain relatively low in comparison to countries further north, but the government has taken steps to regulate certain medical substances. In 2017, Peru legalized the use of medical

marijuana and has since worked on implementing a controlled system for cultivation, distribution, and prescription.

Peru's drug policy continues to focus primarily on enforcement and eradication efforts. However, there is growing dialogue on integrating public health strategies, particularly in areas affected by drug trafficking and rural poverty.




Bolivia: Bolivia is unique in the region for its cultural and legal recognition of the coca leaf, which is used traditionally for medicinal and social purposes by many indigenous communities. While coca cultivation for traditional use is permitted, the government maintains a firm stance against the production and trafficking of illicit drugs derived from coca,

such as cocaine. The country has expressed opposition to the legalization of recreational drugs, citing cultural, social, and legal concerns. While Bolivia continues to work on limiting cartel activity, national policy emphasizes the distinction between traditional coca use and illicit drug trade.



Argentina: Argentina does not currently face a widespread opioid addiction crisis, but continues to experience challenges related to synthetic drug use and the influence of organized criminal networks. In 2020, the country legalized home cultivation and access to medical cannabis, signaling a shift toward more flexible drug policy approaches. Recreational use remains

illegal, although public debate around decriminalization continues. Argentina has strengthened efforts to dismantle drug trafficking networks and promote harm reduction strategies, though the integration of addiction treatment into the public health system remains an area for development.



Chile: Chile's drug policy has gradually evolved in recent years. The government has legalized the medical use of cannabis and has regulated access through pharmacies and licensed cultivation. While opioid addiction is not a major public health issue in Chile, there are increasing concerns regarding synthetic drugs and rising substance use among youth.

Chile continues to debate broader drug reforms and engages in both enforcement and public health approaches. Treatment and prevention programs have expanded, especially in urban centers, although regional disparities in access to care persist.



Uruguay: Uruguay is widely known for being the first country to fully legalize and regulate the recreational use of marijuana, which it did in 2013. This model includes government-controlled production, licensed distribution, and user registration. Uruguay's approach is based on reducing the power of the black market, protecting public health, and ensuring consumer safety.

While opioid addiction is not a major concern domestically, Uruguay's drug policy model has drawn international attention. The government continues to monitor the social and health effects of legalization while advocating for evidence-based and rights-respecting drug policy.



Honduras: Honduras faces serious challenges related to organized crime, drug trafficking, and cartel violence. Although opioid use is not widespread, the dominance of criminal organizations in certain areas has weakened law enforcement, undermined governance, and

contributed to widespread insecurity.

The Honduran government maintains a prohibitionist stance on drugs and has not legalized any substances for recreational or medical purposes. Anti-drug operations remain a national security priority, with limited emphasis on public health or harm reduction measures.

9. Possible Solutions

- Strengthening regional frameworks and bilateral agreements to combat transnational drug trafficking networks, particularly those involved in the production and distribution of synthetic opioids such as fentanyl. This may include improved intelligence sharing, coordinated enforcement operations, and judicial cooperation across borders.
- Implementing or expanding prescription drug monitoring programs (PDMPs) to track the distribution and use of opioid medications. Establishing clear prescribing guidelines for medical professionals to reduce the risk of overprescription or misuse, while ensuring access for legitimate medical needs.
- Developing comprehensive public information campaigns aimed at raising awareness about the risks of opioid misuse, the importance of early intervention, and available treatment options. Campaigns may also work to reduce stigma associated with addiction and recovery.
- In areas affected by illicit drug production, promoting alternative livelihoods and community-based economic development to reduce dependence on the drug trade. This may involve investment in infrastructure, agriculture, education, and employment initiatives.
- Encouraging evidence-based dialogue on the outcomes of drug policy reforms, such as cannabis legalization or the decriminalization of personal drug possession. Member states may examine whether such policies have affected addiction rates, public safety, and black market activity, while respecting national sovereignty and legal traditions.

10. Points to Cover

1. What forms of medical treatment and rehabilitation have proven most effective in addressing opioid dependency, and how can these be made more accessible across OAS member states?
2. In what ways can the influence of drug cartels on regional security and economic stability be diminished through coordinated policy measures?
3. What regulatory mechanisms should be implemented to prevent the overprescription and misuse of pharmaceutical opioids?
4. How can border security cooperation among OAS countries be strengthened to better prevent the trafficking of narcotics and related substances?
5. What are the potential impacts of drug legalization on addiction rates, public health, and the dynamics of the illicit drug market?
6. What types of public education and awareness initiatives could be developed to effectively prevent substance abuse, particularly among vulnerable populations?
7. How can the medical use of controlled substances, including cannabis, be safely regulated within the legal and healthcare frameworks of OAS member states?
8. In what ways can economic development and targeted social programs help reduce the influence of drug cartels, particularly in economically disadvantaged regions?

11. Resources and Links for Further Research

[Polytrauma Rehabilitation Center Design Guide \(va.gov\)](#)

[Drug Facts Sheet: Synthetic Opioids \(dea.gov\)](#)

[Consultation: Prescription strong \(Schedule 8\) opioid use and misuse in Australia – options for a regulatory response \(tga.gov.au\)](#)

[IF12260 \(congress.gov\)](#)

[\(U\) United States: Areas of Influence of Major Mexican Transnational Criminal Organizations \(dea.gov\)](#)

[Mexican drug cartels and their Australian connections: tracking and disrupting dark networks](#)

[R41576.pdf \(fas.org\)](#)

[How Many Addiction Treatment Centers Are In The U.S? \(birchtreerecovery.com\)](#)

[Chart: Synthetic Opioids Like Fentanyl Cause Spike in Overdose Deaths | Statista](#)
[Drug Use and Overdose Statistics - Ottawa Public Health](#)